Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma

This study is testing tegavivint, a new targeted drug that blocks a protein involved in cancer cell survival, in people with relapsed or treatment-resistant large B-cell lymphoma (a type of fast-growing blood cancer) who have specific genetic features in their tumors. **You may be eligible if...** - You have a confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma that has returned or stopped responding to treatment - Your tumor has overexpression of specific proteins (MYC and BCL2) or specific genetic rearrangements (translocations) confirmed by testing - You have had prior treatment, including stem cell transplant or CAR-T cell therapy if eligible - You have measurable disease on imaging **You may NOT be eligible if...** - Your lymphoma does not have the required genetic features - You have not yet tried available standard treatments - Your overall health does not meet the required criteria Talk to your doctor to see if this trial is right for you.